Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Massachusetts General Hospital
Kineta Inc.
Western Sydney Local Health District
Genzada Pharmaceuticals USA, Inc.
SpeciCare
MultiVir, Inc.
Shenzhen BinDeBio Ltd.
Quantgene Inc.
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)